Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 7,545,000 | 6,954,000 | 6,686,000 | 7,114,000 | 7,051,000 |
| Cost of Goods | 1,574,000 | 1,544,000 | 1,552,000 | 2,090,000 | 1,565,000 |
| Gross Profit | 5,971,000 | 5,410,000 | 5,134,000 | 5,024,000 | 5,486,000 |
| Operating Expenses | 5,083,000 | 2,766,000 | 9,456,000 | 3,411,000 | 2,863,000 |
| Operating Income | 888,000 | 2,644,000 | -4,322,000 | 1,612,000 | 2,623,000 |
| Interest Expense | 238,000 | 237,000 | 254,000 | 252,000 | 232,000 |
| Other Income | 306,000 | -354,000 | 90,000 | 293,000 | -73,000 |
| Pre-tax Income | 956,000 | 2,053,000 | -4,486,000 | 1,653,000 | 2,318,000 |
| Income Tax | -297,000 | 438,000 | -315,000 | 236,000 | 146,000 |
| Net Income Continuous | 1,253,000 | 1,615,000 | -4,171,000 | 1,417,000 | 2,172,000 |
| Minority Interests | 0 | N/A | N/A | -12,000 | -8,000 |
| Net Income | $1,253,000 | $1,614,000 | $-4,170,000 | $1,429,000 | $2,180,000 |
| EPS Basic Total Ops | 1.00 | 1.29 | -3.34 | 1.14 | 1.75 |
| EPS Basic Continuous Ops | 1.00 | 1.30 | -3.34 | 1.14 | 1.74 |
| EPS Diluted Total Ops | 1.00 | 1.29 | -3.34 | 1.14 | 1.73 |
| EPS Diluted Continuous Ops | 1.00 | 1.29 | -3.34 | 1.13 | 1.73 |
| EPS Diluted Before Non-Recurring Items | 2.02 | 2.01 | -1.32 | 1.72 | 2.29 |
| EBITDA(a) | $1,578,000 | $3,338,000 | $-3,632,000 | $2,301,000 | $3,307,000 |